Kane Biotech Inc.
KNBIF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.04 | 0.08 | -0.44 | -0.05 |
| FCF Yield | -9.21% | -10.60% | -8.19% | -2.93% |
| EV / EBITDA | -18.02 | -44.33 | -14.04 | -18.33 |
| Quality | ||||
| ROIC | -36.13% | -11.62% | -122.84% | 39.25% |
| Gross Margin | -60.34% | -162.61% | 10.29% | -69.29% |
| Cash Conversion Ratio | 1.15 | 2.22 | 0.91 | 0.39 |
| Growth | ||||
| Revenue 3-Year CAGR | -40.61% | -10.72% | -4.24% | -7.95% |
| Free Cash Flow Growth | 14.43% | 28.38% | -149.08% | 15.64% |
| Safety | ||||
| Net Debt / EBITDA | -2.72 | -5.03 | -1.43 | -1.90 |
| Interest Coverage | -7.56 | -2.63 | -19.79 | -16.35 |
| Efficiency | ||||
| Inventory Turnover | 0.04 | 0.22 | 2.35 | 0.57 |
| Cash Conversion Cycle | 3,627.77 | -413.59 | -150.48 | -279.20 |